Dr Liz Caldon

Liz studies the way that faulty DNA replication and cell divisions can alter the fate of a cancer cell. She received undergraduate degrees in Science and Law from UNSW Sydney, before studying towards a Masters of Science at the University of Toronto, Canada.  Her PhD studies took her back to Sydney

Research Level

Group Leader

Biography

Liz studies the way that faulty DNA replication and cell divisions can alter the fate of a cancer cell. She received undergraduate degrees in Science and Law from UNSW Sydney, before studying towards a Masters of Science at the University of Toronto, Canada.  Her PhD studies took her back to Sydney where she investigated the interaction between hormone signalling and proliferative control of breast cancer cells.  In 2013 she established her own research team at the Garvan Institute, the Replication and Genome Stability Group.

The Replication and Genome Stability group works towards understanding the way that cancer cells evolve due to the selective pressure of therapeutic drugs and cancer driver genes called oncogenes. A primary goal is understanding the evolution of hormone therapy resistance in breast cancer, which is a major cause of breast cancer related death.  Based on their findings on the multistep acquisition of hormone therapy resistance, Liz and her team are focussed on translating knowledge about fundamental breast cancer biology and evolution into targetable therapies that provide clinical benefit.

Liz studies the way that faulty DNA replication and cell divisions can alter the fate of a cancer cell. She received undergraduate degrees in Science and Law from UNSW Sydney, before studying towards a Masters of Science at the University of Toronto, Canada.  Her PhD studies took her back to Sydney where she investigated the interaction between hormone signalling and proliferative control of breast cancer cells.  In 2013 she established her own research team at the Garvan Institute, the Replication and Genome Stability Group.

The Replication and Genome Stability group works towards understanding the way that cancer cells evolve due to the selective pressure of therapeutic drugs and cancer driver genes called oncogenes. A primary goal is understanding the evolution of hormone therapy resistance in breast cancer, which is a major cause of breast cancer related death.  Based on their findings on the multistep acquisition of hormone therapy resistance, Liz and her team are focussed on translating knowledge about fundamental breast cancer biology and evolution into targetable therapies that provide clinical benefit.

Awards and Honours

2018 - The Ridley Ken Davies Award
2017 - Heliflite Young Explorer Award
2017-2020 National Breast Cancer Foundation Career Development Fellowship
2015 - CHAMP Private Equity Young Pioneer Award
2014 - Cancer Institute Career Development Fellowship
2013 - Cure Cancer Conference and Professional Development Grant
2013 - “Best Translational Research Presentation”, Lowy Cancer Symposium, UNSW, Sydney, Australia
2011-2016 - National Breast Cancer Foundation Postdoctoral Fellowship
2011 - Cure Cancer Australia Postdoctoral Fellowship
2010 - Young Garvan Fellowship
2009 - Qantas Research Travel Award
2005-2007 - Cancer Institute NSW Scholar
2004 - Beth Yarrow Scholarship
2003 - LH Ainsworth Scholarship in Cancer Research
2002 - Connaught Graduate Fellowship, University of Toronto

Education

2007 - PhD, University of NSW, Sydney - Australia
2003 - MSc University of Toronto - Canada
2001 - Bachelor of Laws (LLB), University of New South Wales, Sydney - Australia
1998 - BSc (Hons, University Medal) University of New South Wales, Sydney - Australia

Fundings

The amazing organisations that make our research possible are:

  • NBCF (IIRS Grant and NBCF Fellowship)
  • NHMRC (Project Grant)
  • Tour de Cure
  • Perpetual Impact
  • Dr Lee McCormack Edwards Foundation

Selected Publications

 
  1. Du*, S. A. Bert*, N. J. Armstrong, C.E. Caldon, J. Z. Song, S. S. Nair, C. M. Gould, P. Loi Luu, T. Peters, A. Khoury, W. Qu, E. Zotenko, C. Stirzaker, S.J. Clark (2019) “DNA replication timing in concert with epigenome remodelling is associated with the nature of chromosomal rearrangements in cancer “ Nature Communications Accepted *Equal contribution
  2. Currey*, Z. Jahan*, CE. Caldon, P N Tran, F Benthani, P De Lacavalerie, DL Roden, BS Gloss, C Campos, EG Bean, A Bullman, S Reibe-Pal, ME Dinger, MA Febbraio, SJ Clarke, JC Howard, JE Dahlstrom, MRJ Kohonen-Corish (2019)” Mouse model of ‘Mutated in Colorectal Cancer’ gene deletion reveals novel pathways in colitis and cancer.” Cellular and Molecular Gastroenterology and Hepatology. Accepted *Equal contribution
  3. Tadesse, S., E. Caldon, W. Tilley and S. Wang (2019). "Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update." Journal of Medicinal Chemistry. in press
  4. Chia, K., Milioli, H., Portman, N., Laven-Law, G., Coulson, R., Yong, A., Segara, D., Parker, A., Caldon, C., Deng, N., Swarbrick, A., Tilley, W., Hickey, T., & Lim, E. (2019). “Non-canonical AR activity facilitates endocrine resistance in breast cancer”, Endocrine-Related Cancer, 26(2), 251-264.
  5. Portman, N., Alexandrou, S., Carr, E., Wang, S., Lim, E., E. Caldon (2019) “Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer”. Endocrine Related Cancer 26 (1), R15-R30.
  6. Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y, Croucher DR, Sansom OJ, Pajic M, Caldon CE, Morton JP*, Timpson P*. (2018) “Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer”. Cell Reports 23(11):3312-26. *Co-senior
  7. Rogers, S., R. A. McCloy, B. L. Parker, D. Gallego-Ortega, A. M. K. Law, V. T. Chin, J. R. W. Conway, D. Fey, E. K. A. Millar, S. O’Toole, N. Deng, A. Swarbrick, P. D. Chastain, A. J. Cesare, P. Timpson, E. Caldon, D. R. Croucher, D. E. James, D. N. Watkins and A. Burgess (2018). "MASTL overexpression promotes chromosome instability and metastasis in breast cancer." Oncogene 37:4518–4533.
  8. Aziz, D., D. Etemadmoghadam,* E. Caldon,* G. Au-Yeung, N. Deng, R. Hutchinson, D. Bowtell, P. Waring and A. O. C. S. Group (2018). "19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes." Gynecologic Oncology. 151 (2), 327-336 *Equal contribution
  9. Law, A. M. K., J. X. M. Yin, L. Castillo, A. I. J. Young, C. Piggin, S. Rogers, C. E. Caldon, A. Burgess, E. K. A. Millar, S. A. O’Toole, D. Gallego-Ortega, C. J. Ormandy and S. R. Oakes (2017). "Andy’s Algorithms: new automated digital image analysis pipelines for FIJI." Scientific Reports 7(1): 15717.
  10. Caldon, C.E. (2016) Cdk2 regulates metastasis suppressor Cell Cycle, i15(6): 779-780
  11. Rogers, D. Fey, R.A. McCloy, B.L. Parker, N.J. Mitchell, R.J. Payne, R.J. Daly, D.E. James, C.E. Caldon, D.N. Watkins, D.R. Croucher, and A. Burgess (2016) “PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells” Journal of Cell Science 129(7) 1340-1354.
  12. Susanto, J.M., E.K. Colvin, M. Pinese, D.K. Chang, M. Pajic, A. Mawson, E. Caldon, E.A. Musgrove, S.M. Henshall, R.L. Sutherland A.V. Biankin, C.J. Scarlett (2015) “The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2'deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivoInternational Journal of Oncology 46 (5), 2223-2230.
  13. Rogers, S., B.S. Gloss, C.S. Lee, C.M. Sergio, M.E. Dinger, E.A. Musgrove, A. Burgess, E. Caldon. (2015) “Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cellsCell Division 10 (1), 1.
  14. Loh, S.W., Cooper, C., Selinger, C.I., Barnes, E., Chan, C., Carmalt, H., West, R., Gluch, L., Beith, J.M., Caldon, C.E., O'Toole, S. (2015) “Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast.” Journal of Clinical Pathology jclinpath-2014-202331.
  15. Caldon, C.E. (2014) “Estrogen signalling and the DNA damage response in hormone dependent breast cancers.” Frontiers in Oncology 4:106.
  16. McCloy R.A., S. Rogers, E. Caldon, T. Lorca, A. Castro, A. Burgess. (2014) “Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events” Cell Cycle 13 (9), 0-1.
  17. Stone, M.J. Cowley, F. Valdes-Mora, R.A. McCloy, C.M. Sergio, D. Gallego-Ortega, C.E. Caldon, C.J. Ormandy, A.V. Biankin, J.M. Gee, R.I. Nicholson, C.G. Print, S.J. Clark, E.A. Musgrove. (2013) “BCL-2 hypermethylation is a potential biomarker of sensitivity to anti-mitotic chemotherapy in endocrine-resistant breast cancer.” Molecular Cancer Therapeutics 12 (9), 1874-1885
  18. Caldon C.E., C.M. Sergio, A. Burgess, A.J. Deans, R.L. Sutherland, E.A. Musgrove. (2013) “Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1” Cell Cycle 12(4):606-17.

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.

  1. Caldon C.E.*, C.M. Sergio, R.L. Sutherland, E.A. Musgrove. (2013) “Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells” Cell Cycle 12(4):596-605. *Corresponding author

Editorialised in Spoerri et al (2013) Cell Cycle 12(5): 715 and Geng et al (2013) Cell Cycle 12(8):1165.­­

  1. Kalyuga M., D. Gallego-Ortega, H.J. Lee, D.L. Roden, M.J. Cowley, E. Caldon, A. Stone, S.L. Allerdice, F. Valdes-Mora, R. Launchbury, A.L. Statham, N. Armstrong, M.C. Alles, A. Young, A. Egger, W. Au, C.L. Piggin, C.J. Evans, A. Ledger, T. Brummer, S.R. Oakes, W. Kaplan, J.M. Gee, R.I. Nicholson, R.L. Sutherland, A. Swarbrick, M.J. Naylor, S.J. Clark, J.S. Carroll, C.J. Ormandy. (2012) “ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.” PLoS Biology 10(12):e1001461.
  2. Ortiz-Padilla, C., D. Gallego-Ortega, B. C. Browne, F. Hochgrafe, E. Caldon, R. J. Lyons, D. R. Croucher, D. Rickwood, C. J. Ormandy, T. Brummer and R. J. Daly (2012). "Functional characterization of cancer-associated Gab1 mutations." Oncogene 32 (21), 2696-2702
  3. Caldon C.E., C. M. Sergio, J. Kang, A. Muthukaruppan, M. N. Boersma, A. Stone, J. Barraclough, C. S. Lee, M. A. Black, L. D. Miller, J. M. Gee, R. I. Nicholson, R. L. Sutherland, C. G. Print and E. A. Musgrove (2012). "Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells." Molecular Cancer Therapeutics 11(7): 1488-1499.
  4. Musgrove, E. A., E. Caldon, J. Barraclough, A. Stone and R. L. Sutherland (2011). "Cyclin D as a therapeutic target in cancer." Nature Reviews Cancer 11(8): 558-572.
  5. Hilton, H.N., M. Kalyuga, M.J. Cowley, M.C. Alles, H.J. Lee, E. Caldon, K. Blazek, W. Kaplan, E.A. Musgrove, R.J. Daly, M.J. Naylor, J.D. Graham, C.L. Clarke and C.J. Ormandy (2010). "The anti-proliferative effects of progestins in T47D breast cancer cells are tempered by induction of the ETS transcription factor Elf5." Molecular Endocrinology 24(7), 1380-92.
  6. Caldon C.E., R. L. Sutherland and E. A. Musgrove (2010). "Cell cycle proteins in epithelial cell differentiation: Implications for breast cancer." Cell Cycle 9: 10.
  7. Caldon C.E. and E. A. Musgrove (2010). "Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer." Cell Division 5(2).
  8. Caldon C.E., C. M. Sergio, J. Schutte, M. N. Boersma, R. L. Sutherland, J. S. Carroll and E. A. Musgrove (2009). "Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc." Molecular and Cellular Biology 29(17): 4623-4639.
  9. Musgrove, E.A., C.M. Sergio, S. Loi, C.K. Inman, L.R. Anderson, M.C. Alles, M. Pinese, E. Caldon, J. Schutte, M. Gardiner-Garden, C.J. Ormandy, G. McArthur, A.J. Butt and R.L. Sutherland (2008). "Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer." PLoS ONE 3(8): e2987.
  10. Caldon C.E., A. Swarbrick, C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini." Cancer Research 68(8): 3026-3036.
  11. Caldon C.E., C. S. Lee, R. L. Sutherland and E. A. Musgrove (2008). "Wilms' tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation." Oncogene 27(1): 126-138.
  12. Butt, A.J., E. Caldon, C. M. McNeil, A. Swarbrick, E. A. Musgrove and R. L. Sutherland (2008). "Cell cycle machinery: links with genesis and treatment of breast cancer." Advances in Experimental Medicine and Biology 630: 189-205.
  13. Caldon C.E., R. J. Daly, R. L. Sutherland and E. A. Musgrove (2006). "Cell cycle control in breast cancer cells." Journal of Cellular Biochemistry 97(2): 261-274.
  14. Brummer, T., D. Schramek, V. M. Hayes, H. L. Bennett, E. Caldon, E. A. Musgrove and R. J. Daly (2006). "Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein." Journal of Biological Chemistry 281(1): 626-637.
  15. Swarbrick, A., M.C. Akerfeldt, C.S. Lee, C.M. Sergio, E. Caldon, L.J. Hunter, R.L. Sutherland and E.A. Musgrove (2005)"Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1." Oncogene 24(3): 381-9.
  16. Nadkarni, M. A., E. Caldon, K. L. Chhour, I. P. Fisher, F. E. Martin, N. A. Jacques and N. Hunter (2004). "Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria." Journal of Clinical Microbiology 42(11): 5238-5244.
  17. Kus, B. M., E. Caldon, R. Andorn-Broza and A. M. Edwards (2004). "Functional interaction of 13 yeast SCF complexes with a set of yeast E2 enzymes in vitro." Proteins 54(3): 455-467.
  18. Paramaesvaran, M., K. A. Nguyen, Caldon, J. A. McDonald, S. Najdi, G. Gonzaga, D. B. Langley, A. DeCarlo, M. J. Crossley, N. Hunter and C. A. Collyer (2003). "Porphyrin-mediated cell surface heme capture from hemoglobin by Porphyromonas gingivalis." Journal of Bacteriology 185(8): 2528-2537.
  19. Caldon C.E. and P. E. March (2003). "Function of the universally conserved bacterial GTPases." Current Opinion in Microbiology 6(2): 135-139.
  20. Caldon C.E., P. Yoong and P. E. March (2001). "Evolution of a molecular switch: universal bacterial GTPases regulate ribosome function." Molecular Microbiology 41(2): 289-97.